This company listing is no longer active
Satsuma Pharmaceuticals Crecimiento futuro
Future controles de criterios 2/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Satsuma Pharmaceuticals.
Información clave
54.7%
Tasa de crecimiento de los beneficios
68.6%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 20.6% |
| Tasa de crecimiento de los ingresos | 60.3% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 19 May 2023 |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 11 | -20 | N/A | N/A | 4 |
| 12/31/2024 | 3 | -22 | N/A | N/A | 4 |
| 12/31/2023 | N/A | -25 | N/A | N/A | 4 |
| 3/31/2023 | N/A | -65 | -49 | -49 | N/A |
| 12/31/2022 | N/A | -70 | -52 | -52 | N/A |
| 9/30/2022 | N/A | -62 | -53 | -53 | N/A |
| 6/30/2022 | N/A | -61 | -50 | -49 | N/A |
| 3/31/2022 | N/A | -56 | -50 | -49 | N/A |
| 12/31/2021 | N/A | -51 | -45 | -43 | N/A |
| 9/30/2021 | N/A | -48 | -44 | -38 | N/A |
| 6/30/2021 | N/A | -47 | -45 | -39 | N/A |
| 3/31/2021 | N/A | -46 | -44 | -38 | N/A |
| 12/31/2020 | N/A | -48 | -47 | -42 | N/A |
| 9/30/2020 | N/A | -46 | -42 | -41 | N/A |
| 6/30/2020 | N/A | -42 | -42 | -42 | N/A |
| 3/31/2020 | N/A | -37 | -40 | -40 | N/A |
| 12/31/2019 | N/A | -28 | -30 | -30 | N/A |
| 9/30/2019 | N/A | -20 | -25 | -24 | N/A |
| 6/30/2019 | N/A | -13 | -15 | -14 | N/A |
| 3/31/2019 | N/A | -8 | -8 | -8 | N/A |
| 12/31/2018 | N/A | -7 | -7 | -7 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: 1LV is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: 1LV is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: 1LV is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: 1LV's revenue (60.3% per year) is forecast to grow faster than the German market (3.5% per year).
Ingresos de alto crecimiento: 1LV's revenue (60.3% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 1LV's Return on Equity is forecast to be high in 3 years time